Potassium citrate

Description

Potassium citrate is a citrate salt of potassium with the empirical formula K₃C₆H₅O₇ ∙ H₂O. The drug is formulated as extended-release tablets, which are yellowish to tan in color and feature a wax-matrix design. Each tablet contains either 5 mEq (540 mg) or 10 mEq (1080 mg) of potassium citrate. Inactive ingredients in the formulation include carnauba wax and magnesium stearate.

Uses and Indications

Potassium citrate is indicated for the management of renal tubular acidosis (RTA) associated with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis, with or without the presence of calcium stones.

There are no teratogenic or nonteratogenic effects associated with the use of potassium citrate.

Dosage and Administration

For patients with severe hypocitraturia (urinary citrate < 150 mg/day), therapy should be initiated at a dosage of 60 mEq per day. This can be administered as 30 mEq two times per day or 20 mEq three times per day. Doses should be taken with meals or within 30 minutes after meals or at bedtime.

In cases of mild to moderate hypocitraturia (urinary citrate > 150 mg/day), therapy should commence at a dosage of 30 mEq per day. This may be given as 15 mEq two times per day or 10 mEq three times per day, also with meals or within 30 minutes after meals or at bedtime.

It is essential to adhere to these dosing schedules to optimize therapeutic outcomes and ensure patient safety.

Contraindications

Use of this product is contraindicated in the following situations:

Patients with hyperkalemia or conditions predisposing to hyperkalemia, including chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, and extensive tissue breakdown, due to the risk of exacerbating elevated potassium levels.

Patients with gastrointestinal conditions that may cause arrest or delay in tablet passage, such as delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture, as these conditions may hinder proper absorption.

Patients with peptic ulcer disease, as the product may exacerbate gastrointestinal irritation.

Patients with active urinary tract infections, due to the potential for worsening the infection.

Patients with renal insufficiency, specifically those with a glomerular filtration rate of less than 0.7 ml/kg/min, as this may lead to accumulation of the product and increased risk of adverse effects.

Warnings and Precautions

Patients receiving potassium citrate extended-release tablets must be closely monitored for the development of hyperkalemia, particularly in those with compromised renal function or conditions that hinder potassium excretion, such as severe myocardial damage or heart failure. Hyperkalemia can manifest rapidly and may be asymptomatic, leading to potentially fatal cardiac arrest. Therefore, the use of potassium citrate extended-release tablets in patients with chronic renal failure or similar conditions is contraindicated.

In addition, healthcare professionals should be vigilant for gastrointestinal complications. If patients experience severe vomiting, abdominal pain, or gastrointestinal bleeding, the administration of potassium citrate extended-release tablets should be halted immediately. It is essential to investigate the possibility of bowel perforation or obstruction in such cases to prevent further complications.

Regular monitoring of potassium levels and renal function is advisable in patients at risk for hyperkalemia to ensure safe use of this medication.

Side Effects

Patients may experience a range of adverse reactions while using potassium citrate extended-release tablets. Common adverse reactions include minor gastrointestinal complaints such as abdominal discomfort, vomiting, diarrhea, loose bowel movements, or nausea.

Serious adverse reactions have been reported, including hyperkalemia, particularly in patients with impaired mechanisms for excreting potassium. The administration of potassium citrate extended-release tablets can lead to hyperkalemia and potentially fatal cardiac arrest, which may develop rapidly and can be asymptomatic. In cases of severe vomiting, abdominal pain, or gastrointestinal bleeding, it is crucial to discontinue the use of potassium citrate extended-release tablets immediately and investigate the possibility of bowel perforation or obstruction.

Additional considerations include patients with pre-existing conditions that may predispose them to hyperkalemia, such as chronic renal failure, uncontrolled diabetes mellitus, acute dehydration, strenuous physical exercise in unconditioned individuals, adrenal insufficiency, or extensive tissue breakdown. Furthermore, patients who may experience delays in tablet passage through the gastrointestinal tract, including those with delayed gastric emptying, esophageal compression, intestinal obstruction, or stricture, should be monitored closely. Other at-risk populations include patients with peptic ulcer disease, active urinary tract infections, or renal insufficiency, specifically those with a glomerular filtration rate of less than 0.7 ml/kg/min.

Drug Interactions

Concomitant administration of potassium-sparing diuretics is contraindicated due to the potential for severe hyperkalemia. It is advised that these agents be avoided in patients receiving treatment.

Drugs that slow gastrointestinal transit time, including anticholinergics, may exacerbate gastrointestinal irritation associated with potassium salts. Caution is recommended when these agents are used concurrently.

Patients receiving renin-angiotensin-aldosterone inhibitors should be monitored for hyperkalemia, as the combination may increase the risk of elevated potassium levels.

Nonsteroidal anti-inflammatory drugs (NSAIDs) also warrant monitoring for hyperkalemia when used in conjunction with potassium salts, as they may contribute to increased potassium retention.

Packaging & NDC

The table below lists all NDC Code configurations of Potassium Citrate, the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Therefore, the use of this medication in children is not recommended until further data are available to support its use in this population.

Geriatric Use

Elderly patients may not require specific dosage adjustments when using potassium citrate; however, caution is advised due to the potential for impaired mechanisms of potassium excretion commonly seen in this population. This is particularly relevant for geriatric patients with chronic renal failure or other conditions that may compromise potassium elimination.

Close monitoring of serum electrolytes, serum creatinine, and complete blood counts is recommended every four months, with more frequent assessments for those with cardiac disease, renal disease, or acidosis. This monitoring is especially pertinent for elderly patients, who may be at an increased risk for complications.

Elderly patients are at a heightened risk for hyperkalemia, particularly if they have chronic renal failure or other conditions that impair potassium excretion. Therefore, the use of potassium citrate extended-release tablets should be avoided in these patients.

While specific age-related dosage adjustments are not outlined, standard dosing recommendations should be applied with caution in elderly patients, particularly those with reduced kidney function or other comorbidities.

Patients, including elderly individuals, should be counseled to report any signs of gastrointestinal distress or hyperkalemia, such as muscle weakness, fatigue, or palpitations. Regular follow-up and monitoring are essential to ensure safety and efficacy in this population.

Pregnancy

The safety of potassium citrate extended-release tablets during pregnancy has not been established, as animal reproduction studies have not been conducted. There is insufficient data to determine whether these tablets can cause fetal harm or affect reproductive capacity when administered to pregnant patients. Therefore, potassium citrate extended-release tablets should be prescribed to pregnant women only if the potential benefits clearly outweigh the risks. Healthcare professionals are advised to carefully consider the necessity of this treatment in pregnant patients.

Lactation

Potassium citrate extended-release tablets are not known to affect the normal potassium ion content of human milk, which is approximately 13 mEq/L. However, due to the lack of specific data regarding the excretion of potassium citrate in breast milk and its potential effects on breastfed infants, these tablets should be administered to lactating mothers only if clearly needed.

Renal Impairment

Patients with impaired mechanisms for excreting potassium are at an increased risk of hyperkalemia when administered potassium citrate extended-release tablets. This condition can lead to cardiac arrest and may develop rapidly, often without symptoms. Therefore, the use of potassium citrate extended-release tablets is contraindicated in patients with chronic renal failure or any other conditions that significantly impair potassium excretion, such as severe myocardial damage or heart failure. Careful consideration and monitoring are essential in this patient population to prevent potentially fatal outcomes.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

The administration of potassium salts in individuals without predisposing conditions for hyperkalemia is unlikely to result in serious hyperkalemia when dosages are kept within recommended limits. However, it is crucial to recognize that hyperkalemia often presents asymptomatically, typically indicated only by elevated serum potassium levels and specific electrocardiographic changes. These changes may include T-wave peaking, loss of the P-wave, S-T segment depression, and QT interval prolongation. In advanced cases, late manifestations can occur, such as muscle paralysis and cardiovascular collapse due to cardiac arrest.

Management of Hyperkalemia

In the event of hyperkalemia, several treatment measures should be implemented:

1. Monitoring: Patients should be closely monitored for arrhythmias and electrolyte imbalances.

2. Medication Review: It is essential to discontinue any medications containing potassium or those with potassium-sparing properties. This includes potassium-sparing diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), and certain nutritional supplements.

3. Dietary Restrictions: Patients should avoid foods high in potassium, such as almonds, apricots, bananas, various beans (lima, pinto, white), cantaloupe, canned carrot juice, figs, grapefruit juice, halibut, milk, oat bran, potatoes (with skin), salmon, spinach, and tuna.

4. Calcium Administration: Intravenous calcium gluconate may be administered if the patient is at low risk for developing digitalis toxicity.

5. Insulin and Dextrose: An intravenous infusion of 10% dextrose solution containing 10 to 20 units of crystalline insulin per 1,000 mL should be considered, typically at a rate of 300 to 500 mL/hr.

6. Correction of Acidosis: If acidosis is present, intravenous sodium bicarbonate should be used to correct this condition.

7. Dialysis: Hemodialysis or peritoneal dialysis may be necessary for severe cases.

8. Use of Exchange Resins: While exchange resins can be utilized, they should not be relied upon as the sole treatment for acute hyperkalemia.

It is important to note that lowering potassium levels too rapidly in patients who are taking digitalis can lead to digitalis toxicity. Additionally, in patients with impaired potassium excretion mechanisms, such as those with chronic renal failure or severe myocardial damage, the administration of potassium citrate extended-release tablets can lead to hyperkalemia and potentially fatal cardiac arrest. Therefore, the use of potassium citrate extended-release tablets in these populations should be avoided.

Nonclinical Toxicology

Animal reproduction studies have not been conducted to evaluate the potential teratogenic effects of potassium citrate extended-release tablets. Therefore, it is unknown whether this medication can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity. Potassium citrate extended-release tablets should be prescribed to pregnant women only if clearly needed.

Regarding non-teratogenic effects, the normal potassium ion concentration in human milk is approximately 13 mEq/L. However, it remains unclear whether potassium citrate extended-release tablets influence this concentration. Consequently, this medication should be administered to breastfeeding women only if clearly necessary.

No specific details are available concerning nonclinical toxicology or animal pharmacology and toxicology.

Postmarketing Experience

Postmarketing experience has identified the following adverse reactions reported voluntarily or through surveillance programs: hyperkalemia, gastrointestinal disturbances, and allergic reactions, which include rash and pruritus.

Patient Counseling

Advise patients to take each dose of the medication without crushing, chewing, or sucking the tablet to ensure proper absorption and effectiveness. It is important for patients to take this medicine only as directed, particularly if they are also using diuretics and digitalis preparations, as this can affect their treatment regimen.

Patients should be instructed to consult their doctor if they experience any difficulty swallowing the tablets or if they feel that the tablet is sticking in their throat. Additionally, patients must be made aware of the importance of reporting any signs of gastrointestinal bleeding, such as tarry stools, to their doctor immediately.

Inform patients that their healthcare provider will conduct regular blood tests and electrocardiograms to monitor their safety while on this medication. This ongoing assessment is crucial for ensuring the patient's well-being during treatment.

Storage and Handling

The product is supplied in a tight container to ensure its integrity and stability. It is essential to store the product in a manner that prevents exposure to moisture and contaminants. Specific temperature ranges for storage are not provided; however, maintaining a controlled environment is recommended to preserve the product's quality. Special handling requirements include ensuring that the container remains sealed until use to prevent degradation.

Additional Clinical Information

No further data are available.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Potassium Citrate as submitted by Upsher-Smith Laboratories, LLC. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)